[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522784":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":19,"locations":29,"responsibleParty":68,"collaborators":7,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":7,"enrollmentInfo":80,"targetDuration":7,"studyType":83,"phases":7,"briefSummary":84,"conditions":85,"keywords":91,"overallStatus":31,"whyStopped":7,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Gene Solutions","INDUSTRY",null,[9,13,16],{"name":10,"affiliation":11,"role":12},"Sinh D Nguyen, PHD","MGI","PRINCIPAL_INVESTIGATOR",{"name":14,"affiliation":15,"role":12},"Trung Q Lam, MD","University medical center HCMC",{"name":17,"affiliation":18,"role":12},"Samuel J Haryono, MD","MRCCC Siloam Hospitals Semanggi",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Lan NL Tu, PHD","CONTACT","+84888843489","lantu@genesolutions.vn",{"name":26,"role":22,"phone":27,"phoneExt":7,"email":28},"Van T. Phan, MSc","+84908145990","vanphan@genesolutions.vn",[30,45,60],{"facility":18,"status":31,"city":32,"state":7,"zip":7,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Jakarta","Indonesia","ID",{"type":36,"coordinates":37},"Point",[38,39],106.84513,-6.21462,{"lat":39,"lon":38},[42],{"name":17,"role":22,"phone":43,"phoneExt":7,"email":44},"(+62) 021 56967525","samuelharyono@dharmaissurgonc.com",{"facility":46,"status":31,"city":47,"state":7,"zip":7,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"Medical Genetics Institute","Ho Chi Minh City","Vietnam","VN",{"type":36,"coordinates":51},[52,53],106.62965,10.82302,{"lat":53,"lon":52},[56,58],{"name":57,"role":22,"phone":23,"phoneExt":7,"email":24},"Lan NL Tu, PhD",{"name":59,"role":12,"phone":7,"phoneExt":7,"email":7},"Sinh D. Nguyen, PhD. MD",{"facility":61,"status":31,"city":47,"state":7,"zip":7,"country":48,"countryCode":49,"cosmosGeoPoint":62,"geoPoint":64,"contacts":65},"University Medical Center HCMC",{"type":36,"coordinates":63},[52,53],{"lat":53,"lon":52},[66,67],{"name":14,"role":22,"phone":7,"phoneExt":7,"email":7},{"name":14,"role":12,"phone":7,"phoneExt":7,"email":7},{"type":69,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100522784","predicting-breast-cancer-response-to-neoadjuvant-therapy-by-ctdna-assessment-100522784",false,"NCT06087120","Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment","Investigate the Prognostic and Predictive Value of Circulating Tumor DNA (ctDNA) During Neoadjuvant Chemotherapy for Breast Cancer.","BRAVA","Inclusion Criteria:\n\n* Female,18 years old and older,\n* Are diagnosed with stage II-III HER2+\u002FTriple Negative breast cancer and indicated for neoadjuvant chemotherapy,\n* FFPE sample is available at the time of diagnosis and operation,\n* Are voluntary to participate in the study.\n\nExclusion Criteria:\n\n* Recurrent breast cancer,\n* Other cancer metastasis to the breast,\n* Have been or are being treated for cancer,\n* Patients did not agree to participate in the studies.","FEMALE","18 Years",{"count":81,"type":82},125,"ESTIMATED","OBSERVATIONAL","This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.\n\n* Determine the rate of ctDNA positivity at the time before treatment,\n* Determine the rate of ctDNA positivity at the time during treatment,\n* Determine the rate of ctDNA positivity at the time after neoadjuvant therapy, whether there is a change in ctDNA expression of the study population during treatment.\n\nAnd aiming to investigate the relationship between ctDNA expression and MRI imaging with pCR response in neo-adjuvant therapy:\n\n* Correlation between ctDNA detection and pCR response. Determine the percentage of Positive Prediction Value - PPV, Negative Prediction Value - NPV of ctDNA,\n* Correlation between MRI imaging and pCR response. Determination of PPV, NPV of MRI\n* Combination of ctDNA detection and MRI imaging in the prognosis of pCR. Determination of PPV, NPV ratio of ctDNA combined with MRI.",[86,87,88,89,90],"Breast Cancer Female","Stage II Breast Cancer","Stage III Breast Cancer","HER2-positive Breast Cancer","Triple Negative Breast Cancer",[92,93,48,33],"Liquid Biopsy","Circulating Tumour DNA","2025-09-18",{"date":96,"type":97},"2025-09-23","ACTUAL",{"date":99,"type":97},"2023-09-16",{"date":101,"type":82},"2025-12-31",{"name":5,"class":6},3]